Team:Alabama/Parts
Characterization
We created a library of composite parts to further characterize chromoprotein parts K1033925, K1033927, K1033929, K1033930, and K1033931 as part of our intended outreach goals. These parts were generated by fusing promoters J23100, J23101, J23105, J23106, and J23119 to the mentioned chromoprotein parts. This would allow us to test the different chromoproteins with promoters of different strengths in order to test expression levels. We’ll be able to use these upon further testing for outreach programs where we can show kids how to “color with bacteria”. These were submitted as new biobricks K3085001-K3085025.
Contribution
The bulk of our work this summer was doing initial characterization testing and knowledge gap filling in order to adequate chose a system and develop a part to knock out the gene that causes intratumoral bacteria to consume the chemotheraputic drug, gemcitabine.
We developed a cdd knock-out part with biobrick number K3085000. It uses a lambda-red system to knock out the cdd gene that has been identified to cause the resistance, and simultaneously insert chloramphenicol resistance to allow for colony selection and confirmation.
Below is our parts table detailing all 26 parts we created this sea
ahead of us.
<groupparts>iGEM19 Alabama</groupparts>
Characterization
We created a library of composite parts to further characterize chromoprotein parts K1033925, K1033927, K1033929, K1033930, and K1033931 as part of our intended outreach goals. These parts were generated by fusing promoters J23100, J23101, J23105, J23106, and J23119 to the mentioned chromoprotein parts. This would allow us to test the different chromoproteins with promoters of different strengths in order to test expression levels. We’ll be able to use these upon further testing for outreach programs where we can show kids how to “color with bacteria”. These were submitted as new biobricks K3085001-K3085025.
Contribution
The bulk of our work this summer was doing initial characterization testing and knowledge gap filling in order to adequate chose a system and develop a part to knock out the gene that causes intratumoral bacteria to consume the chemotheraputic drug, gemcitabine.
We developed a cdd knock-out part with biobrick number K3085000. It uses a lambda-red system to knock out the cdd gene that has been identified to cause the resistance, and simultaneously insert chloramphenicol resistance to allow for colony selection and confirmation.
Below is our parts table detailing all 26 parts we created this sea
ahead of us.